The

NanoAssemblr®

Spark™

Power to Discover

Explore Novel Genetic Medicine Formulations

Transformative medicines start with novel materials that can be costly or in limited supply. The Spark is ideal for screening novel genetic medicine formulations because it provides:

UNMATCHED RECOVERY

Advanced microfluidics allows microliter formulation volumes with near complete sample recovery.

INTUITIVE OPERATION

Simply pipette starting materials into wells, push a button, and pipette completed formulations out.

RAPID PRODUCTION

The Spark formulation process requires less than 10 seconds, allowing hundreds of formulations to be made in hours.

ROBUST PROCESS

Electronic control minimizes batch-to-batch and user variability.

WORKFLOW INTEGRATION

The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture.

SCALABLE

NxGen microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development.

See How Spark Works for Yourself

The Spark demo will show you how the Spark can integrate into your workflow and accelerate your genetic medicine discovery.

Remarkably Fast and Easy to Use

Start operating the Spark with little to no training. Formulations are ready in seconds. Plus, they can be made on-demand in a sterile hood for immediate cell culture application.

PIPETTE IN

CAP

INSERT

PUSH START

PIPETTE OUT

DILUTE

Accelerate Proof of Concept

Kick-start the validation of novel treatment modalities or formulations. Rapidly explore materials and parameters with minimal consumption of materials.

Optimize Your Nanoparticle and Payload

Optimize mRNA Sequence and Nucleotide Modifications

Screen Targeting Moieties

Screen Targeting Moieties

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Advanced Technology for Advanced Genetic Medicines

Non-turbulent microfluidic mixing provides unparalleled control over nanoparticle assembly that is scalable from discovery to the clinic.

Numbered Circles-01

An aqueous phase and a miscible solvent containing dissolved nanoparticle precursors are injected into

each inlet of the NanoAssemblr cartridge

Numbered Circles-02

Under laminar flow, the two phases do not immediately mix

Numbered Circles-03

Microscopic features engineered into the channel reproducibly control the mixing of the two streams

Numbered Circles-04

Rapid, controlled, homogenous mixing produces homogeneous nanoparticles

Videos

Spark Demo

NanoAssemblr Technology

Cartridges & Kits

SPARK CARTRIDGE

No cleaning or cleaning validation required: Cartridges are single-use and gamma irradiated for sterility. Available in packs of 20.

T-Cell Kit for mRNA Spark - Box and Vials

GENVOY-ILM T CELL KIT FOR MRNA

The GenVoy-ILM T Cell Kit for mRNA is an LNP reagent mix optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNP.

SPARK FORMULATION KITS

Neuro9 kits contain everything you need to encapsulate siRNA into clinically validated lipid nanoparticle (LNP) delivery systems. Kits include a proprietary ionizable cationic lipid.

Spark Brochure

The NanoAssemblr Spark has an operating nanoparticle formulation volume of 25 – 250 μL. By ensuring yields nearing 100%, the Spark is ideal for target validation screening and nanoparticle formulation development that involves scarce or expensive nucleic acid constructs and nanoparticle excipients.

Download Brochure

Resource Center

Application Note

March 15, 2022

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Naturally-occurring Cholesterol Analogues in Lipid Nanoparticles Induce Polymorphic Shape and Enhance Intracel...

S. Patel, N. Ashwanikumar, E. Robinson, Y. Xia, C. Mihai, J.P. Griffith III, S. Hou, A.A. ...

PTCD1 is Required for Mitochondrial Oxidative-phosphorylation: Possible Genetic Association with Alzheimer's D...

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, ...

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

B. Dejanovic, M.A. Huntley, A. De Mazière, W.J. Meilandt, T. Wu, K. Srinivasan and M. Shen...

UNMATCHED RECOVERY

INTUITIVE OPERATION

RAPID PRODUCTION

ROBUST PROCESS

WORKFLOW INTEGRATION

SCALABLE

Videos

Cartridges & Kits

SPARK CARTRIDGE

GENVOY-ILM T CELL KIT FOR MRNA

SPARK FORMULATION KITS

Resource Center

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Naturally-occurring Cholesterol Analogues in Lipid Nanoparticles Induce Polymorphic Shape and Enhance Intracel...

PTCD1 is Required for Mitochondrial Oxidative-phosphorylation: Possible Genetic Association with Alzheimer's D...

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

Robust low-volume production of nanoparticles for genetic manipulation of cells